ArticleRespiratory research2026
Benchtop NMR as a clinical tool for acute respiratory illness: metabolic signatures associated with disease severity.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundAcute respiratory failure remains a major challenge in critical care, and early identification of patients at risk of clinical deterioration is essential. Metabolomics provides a systems-level characterization of disease severity but its clinical implementation is limited by the need for high-resolution Nuclear Magnetic Resonance (NMR) infrastructure. Benchtop NMR offers a compact and potentially scalable alternative. This study aimed to identify serum metabolic signatures associated with respiratory severity and evaluate agreement between benchtop and high-resolution NMR platforms.
methodsSerum samples from COVID-19 patients with acute respiratory failure were classified by respiratory severity (mild, moderate, severe, and very severe). Metabolomic profiling was performed using 500 MHz high-resolution and 80 MHz benchtop NMR systems. Multivariate analyses were used to identify severity-associated metabolic signatures, assess cross-platform agreement, and evaluate associations with clinical variables.
resultsBoth platforms identified consistent metabolic alterations across severity groups. Supervised models achieved accurate discrimination between hospitalized and non-hospitalized patients and between moderate and very severe cases. Twenty-one metabolites, including glutamine, citrate, lactate, phenylalanine, myo-inositol, glycerol, and trimethylamine N-oxide, contributed to group separation. Altered pathways included carbohydrate metabolism, amino acid turnover, lipid metabolism, and tricarboxylic acid cycle intermediates, consistent with hypoxia and immune activation. Several metabolites correlated with inflammatory markers, immune cell counts, and oxygenation parameters. Importantly, benchtop NMR reproduced the key metabolic patterns observed with high-resolution NMR.
conclusionsSerum NMR metabolomics identifies metabolic signatures associated with respiratory severity. The agreement between high-resolution and benchtop NMR supports the feasibility of benchtop systems for clinically accessible patient stratification in acute respiratory disease, with potential applicability beyond COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.